BiotechTube

agenT-797 + Approved ICIs

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tumor, Solid

Conditions

Tumor, Solid

Trial Timeline

Jan 28, 2022 → Jan 2, 2024

NCT ID
NCT05108623

About agenT-797 + Approved ICIs

agenT-797 + Approved ICIs is a phase 1 stage product being developed by MiNK Therapeutics for Tumor, Solid. The current trial status is completed. This product is registered under clinical trial identifier NCT05108623. Target conditions include Tumor, Solid.

What happened to similar drugs?

20 of 20 similar drugs in Tumor, Solid were approved

Approved (20) Terminated (3) Active (0)
✅PexidartinibDaiichi SankyoApproved
✅KRN23Kyowa KirinApproved
✅DurvalumabAstraZenecaApproved
✅aprepitant + Dexamethasone and Ondansetron during CE-treatmentMerckApproved
✅Everolimus (RAD001)NovartisApproved
✅Chromogranin ANovartisApproved
✅Pasireotide + DiazoxideNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05108623Phase 1Completed

Competing Products

20 competing products in Tumor, Solid

See all competitors
ProductCompanyStageHype Score
ALG.APV-527Alligator Bioscience ABPhase 1/2
18
ATOR-1017Alligator Bioscience ABPhase 1
19
ATOR-1015Alligator Bioscience ABPhase 1
19
mRNA-4359ModernaPhase 2
0
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
mRNA-2416ModernaPhase 2
0
E7050EisaiPhase 1
29
FruquintinibHUTCHMEDPhase 1
23
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
BBP-398 + sotorasibBridgeBio PharmaPhase 1
18
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
18
CixutumumabEli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
27
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
27